A major Chinese pharmaceutical company could begin conducting clinical trials of its recently developed inactivated vaccine for Covid-19 on Pakistan citizens.
China’s Sinopharm International Corp., Li Can sent a letter to the National Institute of Health (NIH), Islamabad to begin “clinical trial on Pakistani nationals”.
NIH Executive Director Maj Gen Dr Aamer Ikram speaking to the Dawn said “no action has so far been taken so far”.
“We want to increase the trend of clinical trials in the country. There are a number of laws before it can start; it has to be approved by the ethics committee, but we will start when we get the clearance,” he added.
China has assured Pakistan if the clinical trials prove to be successful, Pakistan would be able to procure it on a high-priority basis.
Sinopharm is a state-owned enterprise that produces more than 80 per cent of the mandatory immunisation needs of China and played a leading role in fighting the Covid-19 crisis in the country.